Merad Pharmaceuticals Limited - Abbreviated accounts 16.3

Merad Pharmaceuticals Limited - Abbreviated accounts 16.3

MERAD PHARMACEUTICALS LIMITED - Company Information

Print Friendly Version

04024112 1.7.15 30.6.16 30.6.16 Company accounts Private Limited Company FY true false true false false true false Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pure040241122015-06-30040241122016-06-30040241122015-07-012016-06-30040241122014-06-30040241122014-07-012015-06-30040241122015-06-3004024112ns12:England2015-07-012016-06-3004024112ns14:PoundSterling2015-07-012016-06-3004024112ns7:Director12015-07-012016-06-3004024112ns7:Director22015-07-012016-06-3004024112ns7:OrdinaryShareClass12015-07-012016-06-3004024112ns5:ImprovementsOrDevelopmentAssets2015-07-012016-06-3004024112ns5:PlantMachinery2015-07-012016-06-3004024112ns7:OrdinaryShareClass12016-06-3004024112ns7:OrdinaryShareClass12015-06-30
REGISTERED NUMBER: 04024112 (England and Wales)















Abbreviated Unaudited Accounts for the Year Ended 30 June 2016

for

Merad Pharmaceuticals Limited

Merad Pharmaceuticals Limited (Registered number: 04024112)

Contents of the Abbreviated Accounts
for the Year Ended 30 June 2016










Page

Abbreviated Balance Sheet 1

Notes to the Abbreviated Accounts 3

Merad Pharmaceuticals Limited (Registered number: 04024112)

Abbreviated Balance Sheet
30 June 2016

2016 2015
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 2 54,140 55,377

CURRENT ASSETS
Debtors 12,936 29,334
Cash at bank 15,300 5,245
28,236 34,579
CREDITORS
Amounts falling due within one year 60,237 54,383
NET CURRENT LIABILITIES (32,001 ) (19,804 )
TOTAL ASSETS LESS CURRENT
LIABILITIES
22,139
35,573

CAPITAL AND RESERVES
Called up share capital 3 100 100
Profit and loss account 22,039 35,473
SHAREHOLDERS' FUNDS 22,139 35,573

The notes form part of these abbreviated accounts

Page 1
Merad Pharmaceuticals Limited (Registered number: 04024112)

Abbreviated Balance Sheet - continued
30 June 2016


The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 June 2016.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 June 2016 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies
Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end
of each financial year and of its profit or loss for each financial year in accordance with the requirements of
Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to
financial statements, so far as applicable to the company.

The abbreviated accounts have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.


The financial statements were approved by the Board of Directors on 30 March 2017 and were signed on its behalf by:




Mrs N Kumar - Director



Dr R Kumar - Director


The notes form part of these abbreviated accounts

Page 2
Merad Pharmaceuticals Limited (Registered number: 04024112)

Notes to the Abbreviated Accounts
for the Year Ended 30 June 2016


1. ACCOUNTING POLICIES

Accounting convention
The financial statements have been prepared under the historical cost convention and in accordance with the
Financial Reporting Standard for Smaller Entities (effective January 2015).

Turnover
Turnover represents net invoiced sales of goods, excluding value added tax.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Improvements to property - 2% on cost
Plant and machinery - 25% - 50% on reducing balance

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance
sheet date.

2. TANGIBLE FIXED ASSETS
Total
£   
COST
At 1 July 2015 95,693
Additions 503
At 30 June 2016 96,196
DEPRECIATION
At 1 July 2015 40,316
Charge for year 1,740
At 30 June 2016 42,056
NET BOOK VALUE
At 30 June 2016 54,140
At 30 June 2015 55,377

3. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2016 2015
value: £    £   
100 Ordinary £1 100 100

Page 3